TY-JUR T1 - 用于多药抗性结核的Amikacin治疗：需要多少监测？JF - 欧洲呼吸期刊Jo - Eur Respir J SP - 1148 LP - 1150 Do - 10.1183 / 09031936.00184312 VL - 42是 - 4 Au - Melchionda，Veronica Au - Wyatt，Harry Au - Capocci，Santino Au - Garcia Medina，Raul Au -Solamalai，Angelita Au - Katiri，Sotira Au - Hopkins，Susan Au - Creplyy，Ian Au - Lipman，Marc Y1 - 2013/10 / 01 UR - //www.qdcxjkg.com/content/42/4/1148。摘要N2 - 编辑：多药抵抗结核（MDR-TB）是一个越来越多的全球问题。世界卫生组织（世卫组织）指导原则状况，涉嫌MDR-TB的所有患者应给予第2组可注射剂，通常是氨基糖苷类。但是，当长时间服用时，这些可能导致肾毒性，神经毒性和不可逆的耳毒性[1,2]。amonoglycoside相关的渐进性听力损失，从高到低对话频率声音（0.5-2 kHz），影响至少19％MDR-TB患者[3,4]。大多数评估基于自我报告的听力损失，这可能会显着估计受影响的真实比例。虽然这两个耳蜗和前庭功能可以被削弱，耳蜗主要是损坏。这使得听力学测试，特别是检测音调阈值变化的串行声图，评估otootoxicity的有用方法，特别是对于非对话超高频损失[3-5]。Despite这一点，没有广泛接受的协议来监控氨基糖苷处理的MDR-TB患者耳毒性。 Weekly to fortnightly audiograms are recommended after baseline evaluation, though financial and logistical barriers can limit this to monthly assessment [4].We sought to determine the practicality of intensive assessments in subjects using long-term amikacin, and whether we detected early changes in high frequency hearing loss that could assist in clinical management and so avoid subjective ototoxicity.A retrospective data review of all MDR-TB patients treated with amikacin at a single site London MDR-TB service between 2009 and 2011 was performed. This included information on audiology testing, renal assessments and serum trough level drug concentration. Amikacin was administered intravenously at 15 mg·kg−1 … ER -